Bard PowerPort Recall 2026: Why Your Port Was Never Recalled — and Why Claims Still Proceed
Was the Bard PowerPort recalled? No. There is no broad FDA recall covering the catheter fracture, migration, and failure allegations at the center of MDL No. 3081 — yet 4,140 lawsuits were pending in that federal litigation as of October 1, 2026. A recall is not required to bring a product-liability claim, and courts are hearing these cases on their merits right now.
Key Facts
- There is no broad recall addressing the catheter fracture, migration, infection, and blood-clot allegations; a limited FDA Class II recall in 2019 covered a small number of devices for an unrelated component issue and was terminated in 2022.
- The federal cases are consolidated as MDL No. 3081 in the District of Arizona before Judge David G. Campbell, with 4,140 lawsuits pending per the JPML's October 1, 2026 report.
- The first bellwether, Cook v. Becton Dickinson (an infection case), ended in a defense verdict on May 8, 2026, with the jury deadlocked on design defect and a new trial sought.
- The second bellwether, Divelbliss v. Becton Dickinson (a catheter-fracture-and-migration case), ended on September 4, 2026 with a $40 million compensatory verdict on design-defect and failure-to-warn claims — no punitive damages were awarded.
- Additional bellwether trials are scheduled for October 13, December 1, 2026, and February 2, 2027.
What a "Recall" Actually Means
A recall is an FDA-supervised action to remove or correct a marketed product that violates the law or presents a health risk. Recalls can be voluntary (company-initiated) or mandatory (ordered by the FDA, which holds that authority for devices). The FDA classifies recalls by severity: a Class II recall covers situations where use may cause temporary or medically reversible harm, with only a remote probability of serious injury. Critically, a recall is a regulatory remedy — not a prerequisite for a lawsuit. A product can remain on the market while courts decide whether it was defectively designed.
The 2019 Limited Recall, Explained
The only PowerPort recall on record is the limited 2019 Class II recall: a small number of devices, a specific component issue — not the catheter material and design concerns at the center of today's lawsuits, which allege the catheter can degrade, fracture, and migrate into the bloodstream, lodging in the heart or lungs (embolization, a detached fragment traveling through the blood). That recall was terminated in 2022. Law firms following the litigation consistently note it did not address the fracture-and-migration allegations — which is why the devices remain implanted and on the market while MDL No. 3081 moves forward.
Why No Broad Recall Has Happened
Three realities explain it. First, the core allegations — catheter material degrading inside the body, inadequate warnings — are being contested in court; Bard Access Systems, C.R. Bard, and parent Becton, Dickinson and Company (BD) defend the design, and the first bellwether ended in a defense verdict. Second, implantable ports are life-sustaining devices providing long-term intravenous access for chemotherapy and other treatments, so regulators weigh any removal against disrupting patients' ongoing care. Third, the litigation itself is the forum testing the defect claims — the September 2026 $40 million plaintiff verdict came because a jury, not a regulator, decided the design-defect question.
No Recall Does Not Mean No Claim
This is the most misunderstood point. Product-liability law lets an injured person sue a manufacturer directly, without any government action first. The federal cases are organized as multidistrict litigation (MDL) — a procedure consolidating similar federal lawsuits before one judge for shared pretrial proceedings, while each plaintiff keeps an individual case. Bellwether trials are representative test cases whose outcomes help both sides value the remaining claims. That machinery is running at full speed: 4,140 cases pending, two bellwethers decided, three more scheduled through February 2027. Compensation varies widely by case, and most settlements are confidential — but this is live litigation with real verdicts.
How to Check Whether Your Port Is a Bard PowerPort
The litigation covers multiple Bard implanted port catheter products sold under the PowerPort brand, so confirming your device comes first. Three records usually identify the manufacturer and model: the patient identification card from implantation, the operative report from the procedure, and the hospital's implant records. If the card is gone, the hospital's medical-records department can supply the operative report. Eligibility generally turns on having had a Bard implanted port system and then suffering a related injury — infection, sepsis, thrombosis, pulmonary embolism, catheter fracture, or migration. A lawyer can match your device and injury against the MDL's criteria from these records alone.
Deadlines and What to Do Next
Filing time depends on your state's statute of limitations — the legal deadline for bringing a claim — generally two to three years for product injuries, but varying by state and by when the injury was discovered (the discovery rule, which can start the clock at diagnosis rather than implantation). Do not assume you are out of time, and do not assume you have time: device-injury deadlines raise questions only a licensed attorney can answer for your facts. Most firms handling these cases work on a contingency fee — a fee paid only from a recovery, nothing upfront — and offer a free evaluation. For the broader picture, see our October 2026 Bard PowerPort lawsuit update and the guide on catheter fracture and migration qualification, and follow Problem Solved for plain-English breakdowns of major money-and-law stories.
Who Benefits From This — and Who Does Not
The absence of a broad recall does not split patients into two equal camps: what decides the benefit is the identified device, the documented injury, and your state's deadline.
Who benefits:
- Patients with a Bard PowerPort whose catheter fractured or migrated: How: Have the device identified from the patient identification card or the operative report, then have the case evaluated within MDL No. 3081, which is proceeding on the merits — including a $40 million plaintiff verdict in September 2026.
- Patients who suffered a severe infection, sepsis, or a blood clot attributed to the device: How: Gather medical records tying the injury to the implant, since the alleged injuries — fracture, migration, infection, clots — must be documented case by case.
- Patients still within their state deadline: How: Check the applicable deadline without delay, while further bellwether trials are scheduled for October 13, December 1, 2026, and February 2, 2027 and the litigation stays active.
Who benefits little or not at all:
- Patients whose only recall connection is the limited 2019 recall: That Class II recall covered a small number of devices for an unrelated component issue and was terminated in 2022: on its own it does not found a claim.
- Patients waiting for a broad recall or a guaranteed amount: No broad recall exists, and outcomes vary: the first bellwether, Cook v. Becton Dickinson, ended on May 8, 2026 with a defense verdict.
- Patients who cannot establish they have a Bard PowerPort: Without the identification card, operative report, or physician confirmation, the manufacturer and model cannot be established — and the case cannot move forward.
Read more: Bard PowerPort lawsuits in 2026: catheter fracture, migration, and who qualifies
Frequently Asked Questions
Was the Bard PowerPort recalled by the FDA?
No broad recall exists covering the fracture, migration, infection, and blood-clot allegations. A limited 2019 FDA Class II recall covered a small number of devices for an unrelated component issue and was terminated in 2022.
Can I sue if my device was never recalled?
Yes. A recall is not required to file a product-liability claim. MDL No. 3081 is proceeding on the merits — including a $40 million plaintiff verdict in September 2026 — with no broad recall in place.
How many Bard PowerPort lawsuits are pending?
4,140 lawsuits were pending in MDL No. 3081 in the District of Arizona as of the JPML's October 1, 2026 report.
What injuries are alleged in the Bard PowerPort lawsuits?
Catheter fracture and migration (fragments traveling to the heart or lungs), severe infections and sepsis, blood clots, thrombosis, and pulmonary embolism — allegedly caused by design defects and inadequate warnings.
How do I find out if I have a Bard PowerPort?
Check your patient identification card from the implantation, request the operative report from the hospital's medical-records department, or ask your physician — these records identify the manufacturer and model.
Who benefits most from the Bard PowerPort lawsuits — and who does not?
Patients with an identified Bard PowerPort who suffered a catheter fracture, migration, severe infection, or documented blood clot benefit most: MDL No. 3081 is proceeding on the merits, with a $40 million plaintiff verdict in September 2026. Patients whose only connection is the limited 2019 recall, which ended in 2022, patients waiting for a broad recall or a guaranteed amount, and patients who cannot establish they have a Bard PowerPort benefit little or not at all. To start, check the device on the identification card or operative report, then consult a licensed attorney promptly, since deadlines vary by state.
Disclaimer: This article is for general information only and is not legal or medical advice. Mass-tort litigation involves individual facts and changing court orders; consult a licensed attorney about your own claim.